Skip to main content
. Author manuscript; available in PMC: 2021 Feb 12.
Published in final edited form as: J Med Chem. 2020 Oct 20;63(21):12873–12886. doi: 10.1021/acs.jmedchem.0c00774

Figure 1.

Figure 1.

The virtual screening of the D3 library of compounds and the experimental test of the most promising hits resulted in the identification of a new type of topoII inhibitor consisting of bicyclic pyrimidines derivatives, which was used to build a structure-activity relationship, from compound 1 (IC50 of 160 µM) to the lead compound 14 (IC50 of 2 µM, ARN-21934).